admin

Citryll announces the appointment of Maarten Kraan as Chief Medical Officer

Dr. Kraan is a rheumatologist who brings more than 25 years of biopharmaceutical development experience. Dr. Kraan joins Citryll after his CMO role at AM-Pharma. Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.

Citryll announces appointments of Eduardo Bravo as CEO and Tim Schenk as CBO 

Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards.

Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors

Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.

Citryll Appoints Sjoerd van Gorp as Director of Operations

Sjoerd will work closely with key development partners to expand the therapeutic utilities of CIT-013, its clinical development candidate and derivatives.

Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology

Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013.

Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies

Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).

Citryll Appoints CTO and CSO

Citryll today announces it has appointed Eric Meldrum as Chief Scientific Officer and that current CSO and co-founder Renato Chirivi will transition into the role of Chief Technology Officer.

Citryll Appoints Chief Medical Officer

Citryll today announced it has appointed Patrick
Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical
development strategy, Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management / Biometrics, and Drug Safety.

Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board

We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of Citryll. Their impressive and complementary track records in drug discovery and development in pharma, biotech and academia will add significant value…

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOM Brabant Ventures, BrightGene and ModiQuest contributing…